Floatz logo

Solu-Cortef

Pancreatic Fistula

Helsinki University Central HospitalPhase 4 / ApprovedActive
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Pancreatic Fistula cohort.

Asset / SponsorPhaseRating
Pasireotide
Helsinki University Central Hospital
Phase 4B
Glubran 2
Minia University
Phase 2CCC
NORMAL HUMAN SERUM ALBUMIN
Universiti Kebangsaan Malaysia Medical Centre
Phase 2CCC

Same molecule, other indications

Solu-Cortef is also rated in:

congenital adrenal hyperplasiaDormant
A
Indicative ·
81 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →